-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, PolyPid's SHIELD II Trial Receives DSMB Recommendation To Continue Enrollment To 800 Patients

Benzinga·12/24/2024 07:15:06
Listen to the news

• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;

• Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application ("NDA") for D-PLEX100 under Fast Track and Breakthrough Therapy Designations, Previously Granted to D-PLEX100 by the FDA;

• Proceeds from this Financing and Exercise of Data-Triggered Warrant Expected to Extend Cash Runway Beyond Potential NDA Approval